Inclisiran is a medicine that lowers LDL, the "bad" cholesterol, in people who have high cholesterol. It is given as a shot under the skin, usually twice a year after the first doses. It works by turning down the liver's production of a protein that keeps cholesterol in the blood.
Every report comes from a Lived member, sent anonymously.
Have you tried Leqvio (Inclisiran) for High Cholesterol (Hypercholesterolemia)?
Inclisiran, sold as Leqvio, is a prescription injection that lowers LDL (low-density lipoprotein) cholesterol, the "bad" cholesterol that builds up in artery walls and raises the risk of heart attack and stroke. It is used alongside diet and exercise in adults with high cholesterol, in adults and children 12 and older with heterozygous familial hypercholesterolemia (an inherited condition, passed down from one parent, that keeps LDL high from birth), and in children 12 and older with the rarer and more severe homozygous form, inherited from both parents. Most people who receive it already take a statin, the standard first cholesterol medicine, and still need their LDL lower, often because they have heart or blood vessel disease or a strong inherited risk. Its main appeal is convenience: after the first two doses it is given only twice a year.
The liver clears LDL from the blood using receptors on its cells, which act like docking points that pull LDL in. A protein called PCSK9 marks those receptors for destruction, so more PCSK9 means fewer receptors and more LDL left circulating. Inclisiran is a small interfering RNA (siRNA), a short piece of genetic material designed to silence one specific instruction inside cells. It is built to be taken up by liver cells, where it breaks down the message the cell uses to make PCSK9. With less PCSK9, more receptors stay active and the liver removes more LDL from the blood. Because the effect lasts for months inside the liver cells, the injections can be spaced far apart. It works differently from the PCSK9 antibody injections Repatha (evolocumab) and Praluent (alirocumab), which block PCSK9 already in the blood and are injected every two to four weeks.
Inclisiran is a single injection under the skin of the belly, upper arm or thigh, given by a nurse or other healthcare professional rather than at home. The same dose is used for adults and children 12 and older. After the first injection, the second comes three months later, and then one every six months. If a dose is late by less than three months, it is given and the original schedule continues. If it is more than three months late, the schedule starts over with a dose, another three months later, and then every six months. Keeping the appointments matters, because the cholesterol-lowering effect fades if doses are missed for long.
Most people have few side effects. The most common is a reaction where the shot was given, such as pain, redness or a rash, which happened in about 8 in 100 people in studies. Joint pain and bronchitis were slightly more frequent than with placebo. Teenagers in studies reported headaches more often than those on placebo. Allergic reactions are uncommon but have included serious ones. Itching or a rash after a dose is worth reporting to the care team promptly. Trouble breathing or swelling of the face, lips, tongue or throat is an emergency: call 911. Anyone who has had a serious allergic reaction to inclisiran should not receive it again.
Inclisiran has no known major drug interactions listed in its US prescribing information, and it is commonly used together with statins and ezetimibe (a pill that reduces how much cholesterol the gut absorbs). Still, the prescriber should have a full list of medicines and supplements. Inclisiran is usually stopped once a pregnancy is recognized. There are no human data, but lowering cholesterol could in theory affect a developing baby, and cholesterol treatment can generally pause during pregnancy with little long-term effect. Anyone planning pregnancy should discuss timing with the prescriber, especially since each dose lasts for months. It is not known whether inclisiran passes into human breast milk, so breastfeeding is a decision to make with the care team.
LDL starts to fall within about two weeks of the first dose. In large studies of adults already on statins, LDL ended up roughly 50% lower than with placebo after a year and a half, so someone starting at 100 mg/dL might reach about 50 mg/dL. Teenagers with inherited high cholesterol saw a smaller drop, around 30%. Results vary, and a blood test about a month or more after starting shows how well it is working for you. It is a long-term treatment: LDL rises again if injections stop. Lowering LDL is well established as a way to reduce heart attacks and strokes, but large trials testing whether inclisiran itself prevents these events are still under way, while statins and PCSK9 antibodies already have that proof. People usually keep taking their other cholesterol medicines and continue regular follow-up for heart risk.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Leqvio (Inclisiran), what you've noticed, or ask the community a question.